Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial.

Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB.

Obstet Gynecol. 2005 Jan;105(1):161-6.

PMID:
15625158
2.

Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial.

Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF.

Obstet Gynecol. 2007 Apr;109(4):823-30.

PMID:
17400842
3.

Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.

Speroff L, Gass M, Constantine G, Olivier S; Study 315 Investigators.

Obstet Gynecol. 2008 Jan;111(1):77-87. doi: 10.1097/01.AOG.0000297371.89129.b3.

PMID:
18165395
4.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
5.

Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.

Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH.

J Clin Oncol. 2011 Oct 10;29(29):3862-8. doi: 10.1200/JCO.2010.33.1298. Epub 2011 Sep 12.

6.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
7.
8.

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW.

J Clin Oncol. 2006 Mar 20;24(9):1409-14. Epub 2006 Feb 27.

9.

Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.

Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.

Am J Obstet Gynecol. 2004 Dec;191(6):1979-88.

PMID:
15592280
10.

Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.

D'Anna R, Cannata ML, Marini H, Atteritano M, Cancellieri F, Corrado F, Triolo O, Rizzo P, Russo S, Gaudio A, Frisina N, Bitto A, Polito F, Minutoli L, Altavilla D, Adamo EB, Squadrito F.

Menopause. 2009 Mar-Apr;16(2):301-6. doi: 10.1097/gme.0b013e318186d7e2.

PMID:
19034051
11.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
12.
13.

Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.

Palacios S, Farias ML, Luebbert H, Gomez G, Yabur JA, Quail DC, Turbi C, Kayath MJ, Almeida MJ, Mönnig E, Nickelsen T.

Am J Obstet Gynecol. 2004 Jul;191(1):121-31.

PMID:
15295352
14.

Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study.

Buijs C, Mom CH, Willemse PH, Marike Boezen H, Maurer JM, Wymenga AN, de Jong RS, Nieboer P, de Vries EG, Mourits MJ.

Breast Cancer Res Treat. 2009 Jun;115(3):573-80. doi: 10.1007/s10549-008-0138-7. Epub 2008 Aug 1.

PMID:
18670875
15.

Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors.

Biglia N, Torta R, Roagna R, Maggiorotto F, Cacciari F, Ponzone R, Kubatzki F, Sismondi P.

Maturitas. 2005 Sep 16;52(1):78-85.

PMID:
16143229
16.

Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.

Rowan JP, Simon JA, Speroff L, Ellman H.

Clin Ther. 2006 Jun;28(6):921-32. Erratum in: Clin Ther. 2006 Aug;28(8):1244.

PMID:
16860174
17.

A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors.

Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Lawrence W, Hanfelt JJ, Hayes DF.

Ann Oncol. 2000 Jan;11(1):17-22.

18.
19.

Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.

Pinkerton JV, Constantine G, Hwang E, Cheng RF; Study 3353 Investigators.

Menopause. 2013 Jan;20(1):28-37. doi: 10.1097/gme.0b013e31826421a8.

PMID:
23010882
20.

A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.

Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S.

Am J Obstet Gynecol. 2009 Feb;200(2):172.e1-10. doi: 10.1016/j.ajog.2008.09.877. Epub 2008 Dec 25.

PMID:
19110224
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk